- Home
- ITRM vs VTMX Comparison
ITRM vs VTMX Comparison
Compare ITRM & VTMX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ITRM
- VTMX
- Stock Information
- Founded
- ITRM 2015
- VTMX 1998
- Country
- ITRM Ireland
- VTMX Mexico
- Employees
- ITRM N/A
- VTMX N/A
- Industry
- ITRM Biotechnology: Pharmaceutical Preparations
- VTMX
- Sector
- ITRM Health Care
- VTMX
- Exchange
- ITRM Nasdaq
- VTMX Nasdaq
- Market Cap
- ITRM 37.7M
- VTMX N/A
- IPO Year
- ITRM 2018
- VTMX 2023
- Fundamental
- Price
- ITRM $1.05
- VTMX $23.89
- Analyst Decision
- ITRM Strong Buy
- VTMX Sell
- Analyst Count
- ITRM 1
- VTMX 2
- Target Price
- ITRM $5.00
- VTMX $27.50
- AVG Volume (30 Days)
- ITRM 300.3K
- VTMX 159.0K
- Earning Date
- ITRM 05-12-2025
- VTMX 04-23-2025
- Dividend Yield
- ITRM N/A
- VTMX 2.91%
- EPS Growth
- ITRM N/A
- VTMX N/A
- EPS
- ITRM N/A
- VTMX 0.25
- Revenue
- ITRM N/A
- VTMX $252,327,122.00
- Revenue This Year
- ITRM N/A
- VTMX $22.81
- Revenue Next Year
- ITRM $150.10
- VTMX $9.13
- P/E Ratio
- ITRM N/A
- VTMX $8.61
- Revenue Growth
- ITRM N/A
- VTMX 17.65
- 52 Week Low
- ITRM $0.81
- VTMX $21.30
- 52 Week High
- ITRM $3.02
- VTMX $37.92
- Technical
- Relative Strength Index (RSI)
- ITRM 30.57
- VTMX 52.60
- Support Level
- ITRM $1.05
- VTMX $21.30
- Resistance Level
- ITRM $1.16
- VTMX $24.50
- Average True Range (ATR)
- ITRM 0.08
- VTMX 1.02
- MACD
- ITRM -0.00
- VTMX 0.17
- Stochastic Oscillator
- ITRM 0.00
- VTMX 64.94
About ITRM Iterum Therapeutics plc
Iterum Therapeutics PLC is a pharmaceutical company dedicated to maximizing the commercial potential of Orlynvah, an oral-branded penem available in the United States and potentially the first and only oral and intravenous (IV) branded penem available globally. Its product Orlynvah has the potential to be a treatment for complicated urinary tract infections caused by the designated microorganisms, without the presence of known toxicities of some other antibiotics. The company operates in a single business segment, which is the development and commercialization of treatments for drug-resistant bacterial infections.